TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* willing to comply with investigator's and protocol's instructions~* patients signature on the informed consent document~* open-angle glaucoma or ocular hypertension~* currently prescribed timolol hemihydrate (once a day (QD) or twice a day (BID))or timolol maleate in sorbate QD as monotherapy or as a part of 2-drug therapy in at least one eye~Exclusion Criteria:~* inability to understand the trial procedures~* inability to give informed consent~* inability to understand, read, or write English~* best corrected visual acuity of 20/200 or worse in each eye~* current moderate to severe infectious or inflammatory condition of the eye or eyelids including~* current moderate to severe dry eye syndrome~* current chronic use of ocular corticosteroids, ocular surgery or intraocular laser surgery to either eye in the prior 3 months~* treated with 3 or more glaucoma medicines in both eye

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Timolol hemihydrate (Type: None): Subjects currently prescribed timolol hemihydrate 0.5% solution.
- Timolol maleate (Type: None): Subjects currently prescribed timolol maleate in sorbate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Have a histologically or cytologically confirmed adenocarcinoma of the prostate Have metastatic disease documented by positive bone scan or by computed tomography or magnetic resonance imaging Have prostate cancer progression documented by prostate specific antigen according to Prostate Cancer Working Group 2 or radiographic progression according to modified RECIST (response evaluation criteria in solid tumors, v1.1) criteria Be asymptomatic from prostate cancer. A score of 0-1 on BPI-SF Question #3 (worst pain in last 24 hours) will be considered asymptomatic Be surgically or medically castrated, with testosterone levels of \<50 ng/dL (\<2.0 nmol/L). If the subject is being treated with luteinizing hormone releasing hormone (LHRH) agonists or antagonists (subjects who have not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to Day 1, Cycle 1 and must be continued throughout the study.~Exclusion Criteria:~Has a history of pituitary or adrenal dysfunction Has an active infection or other medical condition that would contraindicate corticosteroid use Has any chronic medical condition requiring corticosteroid treatment or has received prior corticosteroid treatment for prostate cancer Has a pathological finding consistent with small cell carcinoma of the prostate Has a known brain metastasis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AA + prednisone 5 mg twice daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 5 mg twice daily
- AA + prednisone 5 mg once daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 5 mg once daily dose
- AA + prednisone 2.5 mg twice daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with prednisone 2.5 mg twice daily
- AA + dexamethasone 0.5 mg once daily (Type: EXPERIMENTAL): Abiraterone acetate in combination with dexamethasone 0.5 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Mesenchymal Stromal Cell Therapy in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* EF \< 45 %~* NYHA 2 - 3~Exclusion Criteria:~* Acute coronary syndrome within last 6 weeks.~* Pregnancy~* FEV1 \<1.0~* Cancer~* Any severe disease which could interfere with the treatment or the outcome

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): The number of mesenchymal stromal cells reached after two culture expansion passages.
- 2 (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Drug Monitoring of Voriconazole

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who were 16 years of age or older~* receiving voriconazole in order to treat invasive fungal infections or for empirical use~Exclusion Criteria:~* who experienced the serious side effect of voriconazole~* were hypersensitive to azoles~* had an aminotransferase, bilirubin, or alkaline phosphatase level higher than five times the upper limit of normal

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- non-TDM of voriconazole (Type: NO_INTERVENTION): conventional dose
- TDM of voriconazole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Initial dose:~* 20 to 64 years~* Patients with undergoing mandibular impacted third molar tooth extraction accompanied by lateral bone removal and crown cutting~* Patients with pain that meets both of the following criteria~* Pain intensity (4-categorical): moderate pain or severe pain~* Pain intensity (VAS): 45.0 mm or more~Additional dose:~* Patients with pain that corresponds to 4. Agree or 5. Strongly agree as the answer to the question about the pain intensity during the period from 5 hours to 12 hours post-initial dose of the study drug~Exclusion Criteria:~* Patients with acute inflammatory findings in the oral cavity necessitating treatment~* Patients who are scheduled to receive general anesthesia and analgesics in the process of the eligible tooth extraction

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib 400mg (Type: EXPERIMENTAL): None
- Celecoxib 200mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Vabicaserin in Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, men and women, aged 18 to 65.~* Hospitalization because of an acute exacerbation of schizophrenia with a diagnosis of schizophrenia established greater than 1 year.~* Ability to remain hospitalized for the duration of the screening period and for 4 weeks of double-blind treatment.~Exclusion Criteria:~* Current Axis I primary psychiatric diagnosis other than schizophrenia (DSM-IV-TR criteria).~* Current diagnosis or history of substance abuse or dependence (DSM-IV-TR criteria), including alcohol (except for nicotine), within 3 months before baseline (day -1).~* Subjects taking high or chronic doses of benzodiazepine at the screening evaluation who, in the investigator's judgment, would be likely to have severe withdrawal symptoms upon discontinuation.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): 4mg/day
- 3 (Type: PLACEBO_COMPARATOR): matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Family Based Prevention of Alcohol and Risky Sex for Older Teens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One parent and the teen both had to enroll in the study.~Exclusion Criteria:~* Non-English speaking

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Smart Choices 4 Teens (Type: EXPERIMENTAL): A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
- Control condition (Type: NO_INTERVENTION): This group was provided with websites where information was available regarding the same topics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status classification 1 or 2~* Procedure: hypospadias repair~* Eligible for a pudendal nerve block~Exclusion Criteria:~* parents or patient refusal~* nerve block failure~* Peroperative complication.

- Gender: MALE
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone group (Type: ACTIVE_COMPARATOR): Patients who received 0.15mg/kg of Dexamethasone in 8ml of saline
- Placebo group (Type: PLACEBO_COMPARATOR): Patients who received the same volume of saline as the study group (8ml)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Trigger Finger Release

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Trigger finger diagnosis, recommended for surgical release~* Be in good health other than the trigger finger~* Have realistic expectations of surgical results~* Be willing to undergo surgical or endoscopic treatment~* Understand and be willing to follow all aspects of the study protocol and have signed and dated the Informed Consent Form and the Authorization for Use and Release of Health and Research Study Information (HIPAA) form prior to any study-related procedures being performed~Exclusion Criteria:~* Collagen-vascular, connective tissue, or bleeding disorder~* Pregnancy~* Regional sympathetic dystrophy~* Abscess or infection at time of planned surgery~* Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Endoscopic Release (Type: EXPERIMENTAL): 12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
- Standard Open Release (Type: ACTIVE_COMPARATOR): 12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The ability to understand and sign a written informed consent form~* 16 to 69 years of age at the time of informed consent~* Females of childbearing potential must have a negative pregnancy test and agree to avoidance of pregnancy~* Subject must show QTc \<450 millisecond (msec) or \<480msec with Bundle Branch Block~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 month~* Subjects currently treated with LAM/ADV, ETV or ETV/ADV for greater than 24 weeks~* Chronic hepatitis B ; HBV NDA \>= 4 log10 copies/mL, Chronic hepatitis B with cirrhosis ; HBV NDA \>= 3 log10 copies/mL~* Serum ALT \<= 10 × ULN~* Creatinine clearance \>= 70 mL/min~* Haemoglobin \>= 8 g/dL~* WBC \>= 1,000 /mm3~Exclusion Criteria:~* Decompensated liver disease~* Co-infection with HIV or HCV~* Autoimmune hepatitis rather than chronic hepatitis B~* Subject with serious complication~* Received or have a plan for solid organ or bone marrow transplantation~* Has proximal tubulopathy~* History of hypersensitivity to nucleoside and/or nucleotide analogues~* Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum α-fetoprotein \> 50 ng/mL at screening~* History of HCC~* Received any interferon or HB vaccine therapy within 24 weeks prior to initiation~* Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to initiation~* Received drugs for injection containing glycyrrhizin as the main component within 4 weeks prior to initiation~* Received drugs causing renal impairment, competitors of renal excretion, immunosuppressants, chemotherapeutics and/or corticosteroids within 8 weeks prior to initiation~* Participation in another clinical study within 6 months of study entry or planned participation in another clinical study after entry to this study~* Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the study period~* Psychiatry disorder or cognitive disorder that may affect the subject ability to give informed consent or to follow specified study procedures~* History of alcohol or drug abuse~* Any condition or situation that may interfere with the subject's participation in the study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- GSK548470 300 mg (Type: EXPERIMENTAL): GSK548470 300 mg tablet is administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subject must:~* Provide written informed consent.~* Have a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of opioid dependence.~* Be male or female, 18 to 65 years of age, inclusive.~* If female, have a negative pregnancy test during screening and agree to use an acceptable method of birth control.~Exclusion Criteria:~Subjects must not:~* Have participated in an experimental drug or device study within the last 30 days.~* Be currently (past 30 days from start of screening) engaged in opioid agonist, opioid partial agonist, or opioid antagonist treatment.~* If female, be breast feeding or lactating.~* Have any medical condition that in the opinion of the physician investigator would preclude the subject from completing the study.~* Have any clinically significant non-substance use psychiatric disorder (e.g., schizophrenia).~* Have current suicidal ideation.~* Have a Mini Mental Status Exam score less than 24.~* Have physical dependence on alcohol.~* Have physical dependence on sedative-hypnotics.~* Have active aphthous stomatitis.~* Have active oral herpes.~* Need on-going prescription medications that interact with the P450 3A4 (a member of the cytochrome P450 superfamily of enzymes) system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine soluble film (Type: EXPERIMENTAL): Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours.
- Buprenorphine/naloxone soluble film (Type: EXPERIMENTAL): Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 hepatitis C infection (confirmed at screening)~* Participant has not received any prior treatment for hepatitis C~* Participant must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection~* Must agree to use 2 forms of effective contraception throughout study (both males and females)~Exclusion Criteria:~* Infection with HIV or non genotype 1 hepatitis C~* Liver disease not related to hepatitic C infection~* Hepatic decompensation~* Significant laboratory abnormalities or other active diseases~* Pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis typ 2 diabetes mellitus~* Male and female on diet and exercise regimen, pre-treated with metformin 12 weeks prior to randomisation~* HbA1c equal or greater than 7.0% and less than or equal to 10% at visit 1~* 18 years or more~* BMI equal or less than 45Kg/m2~Exclusion criteria:~* Uncontrolled hyperglycemia defined as glucose more that 13.3 mmol/L after overnight fast during placebo run-in~* Any other antidiabetic drug within 12 weeks prior to randomisation except metformin~* Acute coronary syndrome (non-STEMI, STEMI unstable angina pectoris), stroke or transient ischemic attack within 12 weeks of informed consent~* Indication of liver disease~* Moderate to severe renal impairment~* Bariatric surgery within past 2 years~* Medical history of cancer or treatment for cancer within last 5 years~* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cell~* Contraindications hypersensitivity to concomitant drugs~* Treatment with anti-obesity drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 dose plus metformin (Type: EXPERIMENTAL): Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
- Glimepiride 1-4 mg plus metformin (Type: ACTIVE_COMPARATOR): Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete